Drugs / Pfs25-IMX313
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04271306 | May 2021 → Feb 2024 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1 | NCT04130282 | Sep 2019 → Sep 2020 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06549257 | Jul 2025 → Sep 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfs25-IMX313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04130282 ↗ |
| Modality | Vaccine | “Plasmodium falciparum malaria vaccine candidate Pfs25-IMX313” NCT04130282 ↗ |